Traditionally, robust protein-specific targeting ligand requirements are met by antibodies (Abs). Antibodies however often have significant problems, including high cost, selection difficulties, selectivity problems, preparation difficulties, stability and immunogenicity. The Targeting Core objective is to provide the Projects in the TCCN sets of targeting reagents for the nanoparticles that not only includes """"""""gold standard"""""""" antibodies but novel aptamers and peptides to both endothelial, cancer and stem cells, both to specific cell surface ligands as well as the cells themselves. All projects will use the resources from the Biological Targeting Core. Specifically, the Targeting Core will develop thioaptamers and next-generation Xaptamers for targeting nanoparticles to CD44 (Project 1;
Aim 2), E-Selectin, (Project 1:
Aim 2, Project 2:
Aim 2), VGFR, EGFR, ICAM-1 and cells (Project 3:
Aim 1) and peptides and antibodies via phage display for targeting proteins (Project 1;
Aim 2) and cells (Project 3:
Aim 1; Project 4:
Aim 2). Additionally, the Targeting Core will provide conjugation of targeting ligands and all micro/nanoparticles (Projects 1-3).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151668-04
Application #
8549998
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$151,229
Indirect Cost
$25,560
Name
University of Texas Health Science Center Houston
Department
Type
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Ornelas, Argentina; McCullough, Christopher R; Lu, Zhen et al. (2016) Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer 16:824
Zacharias, Niki M; McCullough, Christopher R; Wagner, Shawn et al. (2016) Towards Real-time Metabolic Profiling of Cancer with Hyperpolarized Succinate. J Mol Imaging Dyn 6:
Hatakeyama, Hiroto; Wu, Sherry Y; Mangala, Lingegowda S et al. (2016) Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol 1402:189-97
Hosoya, Hitomi; Dobroff, Andrey S; Driessen, Wouter H P et al. (2016) Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. Proc Natl Acad Sci U S A 113:1877-82
Tasciotti, Ennio; Cabrera, Fernando J; Evangelopoulos, Michael et al. (2016) The Emerging Role of Nanotechnology in Cell and Organ Transplantation. Transplantation 100:1629-38
Au Yeung, Chi Lam; Co, Ngai-Na; Tsuruga, Tetsushi et al. (2016) Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 7:11150
Zhou, Min; Melancon, Marites; Stafford, R Jason et al. (2016) Precision Nanomedicine Using Dual PET and MR Temperature Imaging-Guided Photothermal Therapy. J Nucl Med 57:1778-1783
Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2016) Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res :
Mi, Yu; Wolfram, Joy; Mu, Chaofeng et al. (2016) Enzyme-responsive multistage vector for drug delivery to tumor tissue. Pharmacol Res 113:92-99
Rupaimoole, R; Ivan, C; Yang, D et al. (2016) Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene 35:4312-20

Showing the most recent 10 out of 308 publications